Adalimumab-induced autoimmune hepatitis

J Clin Gastroenterol. 2010 Jan;44(1):e20-2. doi: 10.1097/MCG.0b013e3181a745e7.

Abstract

Antitumor necrosis factor antibodies are widely used in the treatment of autoimmune diseases. We describe the occurrence of autoimmune hepatitis in a patient treated with adalimumab, a fully human IgG antibody against tumor necrosis factor, for psoriatic arthritis. The patient made a full recovery after discontinuation of adalimumab and treatment with steroids. This is the first reported case of adalimumab-induced autoimmune hepatitis.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Adult
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Chemical and Drug Induced Liver Injury / drug therapy
  • Chemical and Drug Induced Liver Injury / etiology
  • Female
  • Follow-Up Studies
  • Glucocorticoids / therapeutic use
  • Hepatitis, Autoimmune / drug therapy
  • Hepatitis, Autoimmune / etiology*
  • Humans
  • Immunoglobulin G / immunology
  • Prednisone / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Glucocorticoids
  • Immunoglobulin G
  • Adalimumab
  • Prednisone